SAVA is redefining the way people interact with their health by developing the most advanced wearable biosensor science has to offer, capable of accessing bodily information in a painless, real-time and affordable way.

SAVA is redefining the way people interact with their health by developing the most advanced biosensing technology science has to offer, capable of accessing bodily information in a painless,...

2024年6月21日 · SAVA – the startup reinventing health monitoring with its real-time, affordable and painless microsensor – is emerging from five years of stealth today to announce it has raised $8 million in a seed funding round led by Balderton Capital and Exor Ventures.

Today, fellow UK-based startup Sava is announcing an $8m seed round to develop the next generation of the devices. The company is building a new type of CGM, which it says will be less invasive and cheaper than current devices and able to monitor a wider range of chronic conditions and biomarkers in the future.

2024年6月21日 · SAVA is developing the first-ever multi-molecule biosensing wearable capable of detecting biomarkers just below the skin’s surface, enabled by its novel microsensing technology.

SAVA Technologies, co-founded by Imperial bioengineers Renato Circi and Rafael Michal, is working on an innovative approach to continuous health monitoring with its minimally invasive wearable ...

2024年6月27日 · What’s happening: The London-based startup emerged from stealth with an $8M seed round led by Balderton Capital and Exor Ventures, bringing its funding total to $13M. Initially positioned as a CGM to serve the projected 783M to have diabetes by 2045, SAVA’s unique multi-molecule biosensor will also monitor other diseases in the near future.

2024年6月24日 · Multi-molecule biosensing wearable capable of detecting biomarkers just below skin’s surface, with diabetes its first target. SAVA – a startup reinventing health monitoring with its real-time, affordable and painless microsensor – is emerging from five years of stealth with a £6.3 million seed funding round.

SAVA's microsensor offers painless, continuous, and affordable glucose monitoring, addressing the growing demand for continuous glucose monitoring (CGM) devices, a market worth USD 8.2 billion as of 2024 and growing at 10% annually.

At SAVA, the biosensor’s capabilities begin with blood sugar levels, for which continuous glucose monitoring (CGM) devices already exist. However, traditional CGMs don’t provide a user-friendly experience and can be uncomfortable due to the needle insertion process with …